Ida Vanttinen
Overview
Explore the profile of Ida Vanttinen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tambe M, Unterberger S, Kriegbaum M, Vanttinen I, Olgac E, Vaha-Koskela M, et al.
Cell Death Dis
. 2024 Oct;
15(10):750.
PMID: 39414773
Venetoclax plus azacitidine treatment is clinically beneficial for elderly and unfit acute myeloid leukemia (AML) patients. However, the treatment is rarely curative, and relapse due to resistant disease eventually emerges....
2.
Kytola S, Vanttinen I, Vanttinen I, Ruokoranta T, Partanen A, Holopainen A, et al.
Blood
. 2024 Oct;
145(4):409-421.
PMID: 39357056
The B-cell lymphoma 2 inhibitor venetoclax has shown promise for treating acute myeloid leukemia (AML). However, identifying patients likely to respond remains a challenge, especially for those with relapsed/refractory (R/R)...
3.
Satomaa T, Pynnonen H, Aitio O, Hiltunen J, Pitkanen V, Lahteenmaki T, et al.
Mol Cancer Ther
. 2024 Apr;
23(8):1073-1083.
PMID: 38561023
CD33 (Siglec-3) is a cell surface receptor expressed in approximately 90% of acute myeloid leukemia (AML) blasts, making it an attractive target for therapy of AML. Although previous CD33-targeting antibody-drug...
4.
Kuusanmaki H, Kytola S, Vanttinen I, Ruokoranta T, Ranta A, Huuhtanen J, et al.
Haematologica
. 2022 Dec;
108(7):1768-1781.
PMID: 36519325
The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are...
5.
Kuusanmaki H, Dufva O, Vaha-Koskela M, Leppa A, Huuhtanen J, Vanttinen I, et al.
Blood
. 2022 Dec;
141(13):1610-1625.
PMID: 36508699
Myeloid neoplasms with erythroid or megakaryocytic differentiation include pure erythroid leukemia, myelodysplastic syndrome with erythroid features, and acute megakaryoblastic leukemia (FAB M7) and are characterized by poor prognosis and limited...